All News

Recent FDA actions include approvals and clearances in lipid management, CRC screening, contraception, vaginitis testing, and Alzheimer psychosis.

Shpiner examines why physician trust has declined for years and how AI use reflects, not causes, that shift.

Prebiotic sodas contain less sugar than regular soda and fruit drinks, but a new analysis finds they still lag diet soda and sparkling water on sugar content.

Shpiner explains why patients consult AI before a visit and what physicians should do when the tool gets there first.

A Harvard-led analysis of more than 200,000 US adults found healthy plant-based diets lowered cardiometabolic risk regardless of ultra-processed food content.

The FDA-licensed product is room-temperature-stable, rapidly reconstituted, and intended for adult transfusion when other plasma products are unavailable.

Viatris' new once-weekly patch delivers norelgestromin and ethinyl estradiol, with a Pearl Index of 4.14 in the Phase 3 Luminous Study.

As World Hepatitis Day highlights global testing gaps, an expert outlines how primary care can identify at-risk patients sooner.

FDA clearance adds a noninvasive AI-based test for elevated pulmonary capillary wedge pressure to the CorVista System diagnostic platform.

This World Hepatitis Day, 3 expert hepatologists discuss bepirovirsen's functional cure data and weigh primary care against specialized centers for delivering this treatment.

Primary care faces a colorectal cancer screening backlog. Mark Fendrick, MD, describes noninvasive testing and mandatory colonoscopy follow-up.

FDA approves SimpleScreen CRC, Freenome's blood-based colorectal cancer screening test; Abbott to commercialize it in the US this fall.

FDA cleared Roche’s cobas BV/CV assay to detect bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

Topline TRIUMPH-2 and TRIUMPH-3 results showed retatrutide reduced weight by up to 20.8% in adults with type 2 diabetes and 22.6% in adults with CVD.

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

A peer-reviewed study found FDA-cleared IGeneX immunoblot tests detected 58.3% of early Lyme cases vs 30.0% with standard two-tier testing.

Stevan Gonzalez, MD, a transplant specialist, discusses why chronic liver disease often goes undetected and shares practical screening and referral strategies for PCPs.

A new study links semaglutide and tirzepatide to fewer alcohol-related hospitalizations in adults with AUD and diabetes or obesity.